Design Therapeutics, Inc. Common Stock

DSGNNASDAQ • USD
10.65 USD
↘ 0.15 (1.39%)AT CLOSE (03:59 PM EST)
10.67
↗ 0.01 (0.14%)
POST MARKET (AS OF 04:10 PM EST)
Post Market
AS OF 04:10 PM EST
10.67
↗ 0.01 (0.14%)
🟢Market: OPEN

Design Therapeutics, Inc. Common Stock (DSGN) trades at $10.67 per share. Our models show a "Sell" technical signal alongside a "Neutral" fundamental rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, DSGN trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 10, 2026.

Open?$10.64
High?$10.93
Low?$10.36
Prev. Close?$10.80
Volume?264.9K
Avg. Volume?469.7K
VWAP?$10.61
Rel. Volume?0.56x
Bid / Ask
Bid?$9.09 × 100
Ask?$12.31 × 100
Spread?$3.22
Midpoint?$10.70
Valuation & Ratios
Market Cap?691.6M
Shares Out?64.0M
Float?30.5M
Float %?48.7%
P/E Ratio?N/A
P/B Ratio?3.42
EPS?-$1.16
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Employees
60
Market Cap
691.6M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-03-26
Address
6005 HIDDEN VALLEY ROAD
CARLSBAD, CA 92011
Phone: 858-293-4900
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▲ Bullish(+1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
44
Piotroski F-Score?0/9Weak
Altman Z-Score?25.97Safe
Confidence?48%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?20.70%Squeeze Risk
Short Interest?6.3M
Days to Cover?16.2
Free Float30.5M
Avg Daily Volume389.2K
Settlement Date2026-10-30
Financial Health
Current Ratio?16.78Strong
Quick Ratio?16.78Strong
Cash Ratio?1.20Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
50
3.42FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-8.3CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-36.6%WEAK▾
ROA?
S&P
3
-34.2%WEAK▾
Cash Flow & Enterprise
FCF?$-59369000
Enterprise Value?$676.3M
Fundamentals ratios updated end of day